Arrowhead Pharmaceuticals (NASDAQ:ARWR) Hits New 1-Year Low – Time to Sell?

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)’s share price hit a new 52-week low during mid-day trading on Monday . The company traded as low as $16.26 and last traded at $16.43, with a volume of 68011 shares changing hands. The stock had previously closed at $16.97.

Wall Street Analyst Weigh In

ARWR has been the topic of a number of analyst reports. HC Wainwright restated a “buy” rating and issued a $80.00 price objective on shares of Arrowhead Pharmaceuticals in a research report on Wednesday, February 12th. Sanford C. Bernstein reduced their target price on Arrowhead Pharmaceuticals from $27.00 to $24.00 and set a “market perform” rating on the stock in a report on Friday, November 29th. Piper Sandler lowered their target price on Arrowhead Pharmaceuticals from $62.00 to $45.00 and set an “overweight” rating for the company in a research note on Wednesday, November 27th. Citigroup reduced their price target on Arrowhead Pharmaceuticals from $27.00 to $26.00 and set a “neutral” rating on the stock in a research note on Wednesday, November 27th. Finally, StockNews.com raised Arrowhead Pharmaceuticals to a “sell” rating in a research report on Friday, December 20th. One analyst has rated the stock with a sell rating, four have issued a hold rating and six have assigned a buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $41.44.

Arrowhead Pharmaceuticals Price Performance

The company has a debt-to-equity ratio of 7.27, a current ratio of 6.09 and a quick ratio of 6.09. The company has a 50-day simple moving average of $19.39 and a 200-day simple moving average of $20.49. The stock has a market cap of $2.04 billion, a PE ratio of -3.14 and a beta of 0.92.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last posted its quarterly earnings data on Monday, February 10th. The biotechnology company reported ($1.39) EPS for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.97). Sell-side analysts anticipate that Arrowhead Pharmaceuticals, Inc. will post -2.42 EPS for the current fiscal year.

Insider Activity

In related news, Director William D. Waddill sold 3,748 shares of the business’s stock in a transaction that occurred on Monday, December 16th. The stock was sold at an average price of $21.90, for a total transaction of $82,081.20. Following the completion of the transaction, the director now owns 44,125 shares in the company, valued at $966,337.50. The trade was a 7.83 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Christopher Richard Anzalone sold 133,333 shares of the stock in a transaction that occurred on Tuesday, March 4th. The stock was sold at an average price of $17.02, for a total value of $2,269,327.66. Following the completion of the transaction, the chief executive officer now directly owns 3,773,802 shares of the company’s stock, valued at $64,230,110.04. This trade represents a 3.41 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 280,765 shares of company stock worth $5,227,313. 4.30% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Mackenzie Financial Corp purchased a new stake in Arrowhead Pharmaceuticals in the 4th quarter worth approximately $137,000. GF Fund Management CO. LTD. purchased a new stake in shares of Arrowhead Pharmaceuticals during the fourth quarter worth $49,000. Neo Ivy Capital Management acquired a new stake in Arrowhead Pharmaceuticals during the fourth quarter valued at $318,000. Two Sigma Advisers LP grew its stake in Arrowhead Pharmaceuticals by 330.7% in the fourth quarter. Two Sigma Advisers LP now owns 430,700 shares of the biotechnology company’s stock valued at $8,097,000 after purchasing an additional 330,700 shares in the last quarter. Finally, Two Sigma Investments LP grew its stake in Arrowhead Pharmaceuticals by 281.3% in the fourth quarter. Two Sigma Investments LP now owns 794,373 shares of the biotechnology company’s stock valued at $14,934,000 after purchasing an additional 586,062 shares in the last quarter. 62.61% of the stock is owned by hedge funds and other institutional investors.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.